Bumadizone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H22N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ATD81G944M, chemically known as 2-(2,3-diphenylcarbazoyl)hexansaeure but generally known as bumadizone, which bears US NIH Compound Identifier 19161. Bumadizone most often comes in base and calcium forms. European Medicines Agency schedules Bumadizone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05968MIG. The term BUMADIZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules bumadizone in its Anatomical Therapeutic Chemical (ATC) Classification. BUMADIZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bumadizone under HS 29280090 and SITC 51486. As of Q4 2014, BUMADIZONE remains the US FDA Preferred Term for this commodity. Bumadizone bears US NLM identifiers UMLS ID C0054219 and NCI Concept Code C72113. SMILES: O=C(N(NC1CCCCC1)C1CCCCC1)C(CCCC)C(=O)O.